Crossmark

Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials

Crossref DOI link: https://doi.org/10.1186/s12885-025-14289-4

Published Online: 2025-06-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

El-Jammal, Mohamad

Saifi, Omran

Bazan, Jose

Zeidan, Youssef H.
License Information

Text and Data Mining valid from 2025-06-04

Version of Record valid from 2025-06-04
More Information

Article History

Received: 19 February 2025

Accepted: 7 May 2025

First Online: 4 June 2025

Declarations

:

: Not applicable. Consents were initially collected as part of TRYPHAENA and NeoSphere Trials. This is a retrospective study on prospectively collected data approved by Vivli data agreement.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below